Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ultragenyx Pharmaceutical Inc. (RARE : NSDQ)
 
 • Company Description   
Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Number of Employees: 1,294

 
 • Price / Volume Information   
Yesterday's Closing Price: $39.91 Daily Weekly Monthly
20 Day Moving Average: 1,067,659 shares
Shares Outstanding: 94.54 (millions)
Market Capitalization: $3,773.17 (millions)
Beta: 0.26
52 Week High: $60.37
52 Week Low: $29.59
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 8.13% 2.27%
12 Week 20.36% 0.97%
Year To Date -5.13% -11.14%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
60 Leveroni Court
-
Novato,CA 94949
USA
ph: 415-483-8800
fax: 415-483-8810
ir@ultragenyx.com http://www.ultragenyx.com
 
 • General Corporate Information   
Officers
Emil D. Kakkis - President and Chief Executive Officer
Daniel G. Welch - Chairman
Howard Horn - Executive Vice President; Chief Financial Officer;
Theodore A. Huizenga - Senior Vice President and Chief Accounting Officer
Deborah Dunsire - Director

Peer Information
Ultragenyx Pharmaceutical Inc. (CORR.)
Ultragenyx Pharmaceutical Inc. (RSPI)
Ultragenyx Pharmaceutical Inc. (CGXP)
Ultragenyx Pharmaceutical Inc. (BGEN)
Ultragenyx Pharmaceutical Inc. (GTBP)
Ultragenyx Pharmaceutical Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 90400D108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 94.54
Most Recent Split Date: (:1)
Beta: 0.26
Market Capitalization: $3,773.17 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 21.78% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 25.98
Price/Cash Flow: -
Price / Sales: 6.39
EPS Growth
vs. Year Ago Period: 22.66%
vs. Previous Quarter: -12.95%
Sales Growth
vs. Year Ago Period: 27.99%
vs. Previous Quarter: -15.52%
ROE
06/30/25 - -
03/31/25 - -186.49
12/31/24 - -193.80
ROA
06/30/25 - -
03/31/25 - -36.81
12/31/24 - -38.15
Current Ratio
06/30/25 - -
03/31/25 - 2.40
12/31/24 - 2.37
Quick Ratio
06/30/25 - -
03/31/25 - 2.24
12/31/24 - 2.24
Operating Margin
06/30/25 - -
03/31/25 - -93.04
12/31/24 - -101.60
Net Margin
06/30/25 - -
03/31/25 - -93.04
12/31/24 - -101.60
Pre-Tax Margin
06/30/25 - -
03/31/25 - -92.62
12/31/24 - -101.31
Book Value
06/30/25 - -
03/31/25 - 1.54
12/31/24 - 2.76
Inventory Turnover
06/30/25 - -
03/31/25 - 2.01
12/31/24 - 1.87
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 4.63
12/31/24 - 2.67
 

Powered by Zacks Investment Research ©